{
    "hands_on_practices": [
        {
            "introduction": "Understanding the relationship between molecular pathways and intraocular pressure (IOP) is fundamental to glaucoma research. This exercise provides a quantitative look at how a specific molecular change—increased resistance in the trabecular meshwork due to TGF-β2 signaling—translates into a measurable increase in IOP. By applying the Goldmann equation, you will directly model the pathophysiological consequences of altered aqueous humor dynamics, bridging the gap from cell biology to clinical manometry .",
            "id": "4692759",
            "problem": "In primary open-angle glaucoma, increased Transforming Growth Factor-beta 2 (TGF-β2) signaling in the aqueous humor upregulates extracellular matrix deposition in the trabecular meshwork (TM), increasing hydraulic resistance to conventional outflow. Conventional outflow dynamics are modeled by the Goldmann equation, which relates aqueous humor production to outflow as $F_{\\mathrm{in}} = C(\\mathrm{IOP} - P_{e}) + F_{u}$, where $F_{\\mathrm{in}}$ is aqueous inflow, $C$ is outflow facility, $\\mathrm{IOP}$ is intraocular pressure (IOP), $P_{e}$ is episcleral venous pressure, and $F_{u}$ is uveoscleral outflow. A constitutive relation links facility and resistance as $C = 1/R$, where $R$ is the hydraulic resistance of the TM outflow pathway.\n\nAssume baseline values $F_{\\mathrm{in}} = 2.5 \\ \\mu\\text{L/min}$, $F_{u} = 0.5 \\ \\mu\\text{L/min}$, $P_{e} = 9 \\ \\text{mmHg}$, and baseline outflow facility $C_{0} = 0.3 \\ \\mu\\text{L/min/mmHg}$. Under sustained TGF-β2 exposure, suppose trabecular meshwork resistance doubles from its baseline $R_{0}$ to $R_{1} = 2R_{0}$, with no change in $F_{\\mathrm{in}}$ or $F_{u}$.\n\nStarting from the definitions above and without assuming any additional shortcut formulas, derive the new outflow facility $C_{1}$, then derive expressions for the baseline intraocular pressure $\\mathrm{IOP}_{0}$ and the post-change intraocular pressure $\\mathrm{IOP}_{1}$. Compute the magnitude of the change $\\Delta \\mathrm{IOP} = \\mathrm{IOP}_{1} - \\mathrm{IOP}_{0}$ and state qualitatively whether IOP increases or decreases. Express the final numerical value of $\\Delta \\mathrm{IOP}$ in millimeters of mercury (mmHg) and round your final answer to four significant figures.",
            "solution": "The problem is first subjected to validation.\n\n### Step 1: Extract Givens\n- **Model Equation (Goldmann equation)**: $F_{\\mathrm{in}} = C(\\mathrm{IOP} - P_{e}) + F_{u}$\n- **Constitutive Relation**: $C = 1/R$\n- **Baseline Values**:\n  - Aqueous inflow, $F_{\\mathrm{in}} = 2.5 \\ \\mu\\text{L/min}$\n  - Uveoscleral outflow, $F_{u} = 0.5 \\ \\mu\\text{L/min}$\n  - Episcleral venous pressure, $P_{e} = 9 \\ \\text{mmHg}$\n  - Baseline outflow facility, $C_{0} = 0.3 \\ \\mu\\text{L/min/mmHg}$\n- **Condition of Change**: Trabecular meshwork resistance doubles, $R_{1} = 2R_{0}$.\n- **Constraints**: $F_{\\mathrm{in}}$ and $F_{u}$ remain constant.\n- **Required Tasks**:\n  1. Derive the new outflow facility, $C_{1}$.\n  2. Derive expressions for baseline $\\mathrm{IOP}_{0}$ and post-change $\\mathrm{IOP}_{1}$.\n  3. Compute the change $\\Delta \\mathrm{IOP} = \\mathrm{IOP}_{1} - \\mathrm{IOP}_{0}$.\n  4. State qualitatively if IOP increases or decreases.\n  5. Provide the numerical value of $\\Delta \\mathrm{IOP}$ in mmHg, rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientific Grounding**: The problem is grounded in established physiological principles of aqueous humor dynamics in the eye. The Goldmann equation is a standard, albeit simplified, model used in ophthalmology. The premise that increased TGF-β2 signaling leads to increased trabecular meshwork resistance is a central and well-documented mechanism in the pathophysiology of primary open-angle glaucoma. The numerical values provided are within accepted physiological ranges.\n- **Well-Posedness**: The problem is well-posed. It supplies all necessary parameters and defines a clear set of tasks that lead to a unique, stable, and meaningful solution.\n- **Objectivity**: The problem is stated using precise, objective scientific terminology.\n- **Consistency and Completeness**: The problem is self-contained. The units are consistent throughout: $F_{\\mathrm{in}}$ and $F_{u}$ are in $\\mu\\text{L/min}$, $P_{e}$ and $\\mathrm{IOP}$ are in mmHg, and $C$ is in $\\mu\\text{L/min/mmHg}$, satisfying the dimensional balance of the Goldmann equation.\n- **Realism**: The premise of resistance doubling is a plausible pathological change in the context of glaucoma progression.\n\n### Step 3: Verdict and Action\nThe problem is scientifically sound, well-posed, and internally consistent. It is deemed **valid**. The solution will now be derived.\n\nThe solution proceeds by following the tasks outlined in the problem statement. All derivations begin from the provided fundamental equations.\n\nFirst, we derive the new outflow facility, $C_{1}$. The relationship between outflow facility $C$ and hydraulic resistance $R$ is given as $C = 1/R$.\nThe baseline resistance, $R_{0}$, is the inverse of the baseline facility, $C_{0}$:\n$$R_{0} = \\frac{1}{C_{0}}$$\nThe problem states that under sustained TGF-β2 exposure, the resistance doubles. The new resistance, $R_{1}$, is therefore:\n$$R_{1} = 2R_{0} = \\frac{2}{C_{0}}$$\nThe new outflow facility, $C_{1}$, is the inverse of the new resistance, $R_{1}$:\n$$C_{1} = \\frac{1}{R_{1}} = \\frac{1}{2/C_{0}} = \\frac{C_{0}}{2}$$\nThis is the expression for the new outflow facility. Given $C_{0} = 0.3 \\ \\mu\\text{L/min/mmHg}$, the value of $C_1$ is:\n$$C_{1} = \\frac{0.3}{2} = 0.15 \\ \\mu\\text{L/min/mmHg}$$\n\nNext, we derive the general expression for intraocular pressure (IOP) by rearranging the Goldmann equation:\n$$F_{\\mathrm{in}} = C(\\mathrm{IOP} - P_{e}) + F_{u}$$\nThe flow through the conventional (trabecular) outflow pathway is $F_{\\mathrm{in}} - F_{u}$.\n$$F_{\\mathrm{in}} - F_{u} = C(\\mathrm{IOP} - P_{e})$$\nDividing by $C$ and isolating $\\mathrm{IOP}$ gives:\n$$\\frac{F_{\\mathrm{in}} - F_{u}}{C} = \\mathrm{IOP} - P_{e}$$\n$$\\mathrm{IOP} = \\frac{F_{\\mathrm{in}} - F_{u}}{C} + P_{e}$$\nThis is the general expression for $\\mathrm{IOP}$.\n\nUsing this general expression, we can write the expressions for the baseline intraocular pressure, $\\mathrm{IOP}_{0}$, and the post-change intraocular pressure, $\\mathrm{IOP}_{1}$:\n$$\\mathrm{IOP}_{0} = \\frac{F_{\\mathrm{in}} - F_{u}}{C_{0}} + P_{e}$$\n$$\\mathrm{IOP}_{1} = \\frac{F_{\\mathrm{in}} - F_{u}}{C_{1}} + P_{e}$$\n\nNow, we compute the change in intraocular pressure, $\\Delta \\mathrm{IOP} = \\mathrm{IOP}_{1} - \\mathrm{IOP}_{0}$:\n$$\\Delta \\mathrm{IOP} = \\left(\\frac{F_{\\mathrm{in}} - F_{u}}{C_{1}} + P_{e}\\right) - \\left(\\frac{F_{\\mathrm{in}} - F_{u}}{C_{0}} + P_{e}\\right)$$\nThe term $P_{e}$ cancels out:\n$$\\Delta \\mathrm{IOP} = \\frac{F_{\\mathrm{in}} - F_{u}}{C_{1}} - \\frac{F_{\\mathrm{in}} - F_{u}}{C_{0}}$$\nFactoring out the net conventional outflow term, $(F_{\\mathrm{in}} - F_{u})$:\n$$\\Delta \\mathrm{IOP} = (F_{\\mathrm{in}} - F_{u})\\left(\\frac{1}{C_{1}} - \\frac{1}{C_{0}}\\right)$$\nWe can substitute our derived expression $C_{1} = C_{0}/2$ into this equation:\n$$\\Delta \\mathrm{IOP} = (F_{\\mathrm{in}} - F_{u})\\left(\\frac{1}{C_{0}/2} - \\frac{1}{C_{0}}\\right)$$\n$$\\Delta \\mathrm{IOP} = (F_{\\mathrm{in}} - F_{u})\\left(\\frac{2}{C_{0}} - \\frac{1}{C_{0}}\\right)$$\n$$\\Delta \\mathrm{IOP} = (F_{\\mathrm{in}} - F_{u})\\left(\\frac{1}{C_{0}}\\right) = \\frac{F_{\\mathrm{in}} - F_{u}}{C_{0}}$$\nThis elegant result gives the change in IOP purely in terms of the initial parameters.\n\nQualitatively, since aqueous humor must be produced and flow out of the eye for it to be a viable system, $F_{\\mathrm{in}} > F_{u}$. Also, the outflow facility $C_{0}$ must be positive. Therefore, the term $\\frac{F_{\\mathrm{in}} - F_{u}}{C_{0}}$ is positive, which means $\\Delta \\mathrm{IOP} > 0$. Qualitatively, the intraocular pressure **increases**. This is consistent with the pathology described, where increased resistance to outflow causes a buildup of pressure.\n\nFinally, we compute the numerical value of $\\Delta \\mathrm{IOP}$ using the provided values:\n$F_{\\mathrm{in}} = 2.5 \\ \\mu\\text{L/min}$\n$F_{u} = 0.5 \\ \\mu\\text{L/min}$\n$C_{0} = 0.3 \\ \\mu\\text{L/min/mmHg}$\n\nSubstituting these into our derived expression for $\\Delta \\mathrm{IOP}$:\n$$\\Delta \\mathrm{IOP} = \\frac{2.5 - 0.5}{0.3} = \\frac{2.0}{0.3}$$\n$$\\Delta \\mathrm{IOP} = \\frac{20}{3} \\approx 6.6666... \\ \\text{mmHg}$$\nThe problem requires the answer to be rounded to four significant figures.\n$$\\Delta \\mathrm{IOP} \\approx 6.667 \\ \\text{mmHg}$$",
            "answer": "$$\\boxed{6.667}$$"
        },
        {
            "introduction": "The genetic basis of glaucoma can be complex, often involving multiple pathogenic variants even within a single gene. This problem uses the principles of population genetics to explore this phenomenon, known as allelic heterogeneity, in Primary Congenital Glaucoma (PCG) . By applying Hardy-Weinberg Equilibrium to a founder population, you will learn to infer the collective frequency of uncharacterized pathogenic alleles based on observed disease prevalence, a critical skill in genetic epidemiology.",
            "id": "4692791",
            "problem": "In a founder population with a known pathogenic allele in cytochrome P450 family 1 subfamily B member 1 (CYP1B1), Primary Congenital Glaucoma (PCG) is modeled as a fully penetrant, autosomal recessive disorder in which any biallelic combination of pathogenic CYP1B1 alleles (including compound heterozygotes) leads to disease. Assume random mating, negligible new mutation and migration, and Hardy–Weinberg Equilibrium (HWE). The founder allele has a population allele frequency of $1\\%$ and the observed prevalence of PCG in this population is $1$ in $2{,}500$.\n\nStarting from the HWE genotype frequency definitions and the definition of prevalence for an autosomal recessive trait with multiple pathogenic alleles, and without invoking any pre-derived shortcut formulas, do the following:\n\n1) Derive the expected frequency of individuals homozygous for the founder CYP1B1 allele.\n\n2) Using the observed prevalence and the assumptions above, infer the minimum aggregate allele frequency of all other (non-founder) pathogenic CYP1B1 alleles that is consistent with the observed prevalence.\n\nReport your answers for parts (1) and (2) as decimals. Round your answers to three significant figures. No units are required.",
            "solution": "The problem will be validated before a solution is attempted.\n\n### Step 1: Extract Givens\n-   **Disease:** Primary Congenital Glaucoma (PCG).\n-   **Gene:** Cytochrome P450 family 1 subfamily B member 1 (CYP1B1).\n-   **Inheritance Model:** Fully penetrant, autosomal recessive.\n-   **Condition for Disease:** Any biallelic combination of pathogenic CYP1B1 alleles (including compound heterozygotes).\n-   **Population Assumptions:** Random mating, negligible new mutation and migration, Hardy–Weinberg Equilibrium (HWE).\n-   **Founder Allele Frequency:** $1\\%$ ($p_f = 0.01$).\n-   **Observed PCG Prevalence:** $1$ in $2,500$ ($Prevalence = 0.0004$).\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientifically Grounded:** The problem is grounded in established principles of medical and population genetics. The link between PCG and mutations in the CYP1B1 gene, its autosomal recessive inheritance pattern, and the use of the Hardy-Weinberg Equilibrium model are all standard concepts in the field.\n2.  **Well-Posed:** The problem is well-posed. It provides sufficient information and clear, quantitative questions that allow for the derivation of a unique solution under the specified assumptions.\n3.  **Objective:** The problem is stated in precise, objective, and technical language, free from subjective or ambiguous terms.\n4.  **Consistency Check:** The given prevalence ($1/2500 = 0.0004$) is greater than the prevalence that would be caused by the founder allele alone ($p_f^2 = (0.01)^2 = 0.0001$). This internal consistency is what makes the second part of the question meaningful, as it necessitates the existence of other pathogenic alleles to account for the observed disease frequency.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. It is scientifically sound, well-posed, objective, and internally consistent. A solution will be derived from first principles as requested.\n\n### Solution Derivation\nLet us define the allele frequencies for the gene pool. Let $p_f$ be the frequency of the pathogenic founder allele. Let $p_o$ be the aggregate frequency of all other pathogenic alleles in the CYP1B1 gene. Let $q$ be the aggregate frequency of all non-pathogenic (wild-type) alleles. The sum of all allele frequencies in the population must equal $1$.\n$$p_f + p_o + q = 1$$\nThe problem states that the population is in Hardy–Weinberg Equilibrium (HWE). Therefore, the genotype frequencies are given by the terms in the expansion of $(p_f + p_o + q)^2$.\n$$(p_f + p_o + q)^2 = p_f^2 + p_o^2 + q^2 + 2p_f p_o + 2p_f q + 2p_o q = 1$$\nThe disease is described as a fully penetrant, autosomal recessive disorder where any individual with two pathogenic alleles is affected. The pathogenic alleles are the founder allele (frequency $p_f$) and the group of \"other\" pathogenic alleles (aggregate frequency $p_o$). The genotypes that result in the disease phenotype are:\n1.  Homozygous for the founder allele: Genotype frequency is $f(ff) = p_f^2$.\n2.  Compound heterozygous, with one founder allele and one \"other\" pathogenic allele: Genotype frequency is $f(fo) = 2p_f p_o$.\n3.  Homozygous for an \"other\" pathogenic allele or compound heterozygous for two different \"other\" pathogenic alleles: The aggregate frequency for all such combinations is $f(oo) = p_o^2$.\n\nThe total prevalence of the disease in the population is the sum of the frequencies of all affected genotypes. This derivation starts from the fundamental HWE genotype frequencies as required.\n$$Prevalence = f(ff) + f(fo) + f(oo) = p_f^2 + 2p_f p_o + p_o^2$$\nThis expression is a perfect square trinomial, which simplifies to:\n$$Prevalence = (p_f + p_o)^2$$\nThis equation establishes the direct relationship between the aggregate frequency of all pathogenic alleles and the total disease prevalence under the given model.\n\n**1) Expected frequency of individuals homozygous for the founder CYP1B1 allele:**\nThe problem provides the frequency of the founder allele as $p_f = 1\\%$.\n$$p_f = 0.01$$\nThe frequency of individuals homozygous for this allele is, by the HWE principle, $p_f^2$.\n$$f(ff) = p_f^2 = (0.01)^2 = 0.0001$$\nRounding to three significant figures, the frequency is $0.000100$.\n\n**2) Minimum aggregate allele frequency of all other pathogenic CYP1B1 alleles:**\nThe problem provides the observed prevalence of PCG.\n$$Prevalence = \\frac{1}{2,500} = 0.0004$$\nUsing the derived relationship for prevalence:\n$$Prevalence = (p_f + p_o)^2$$\n$$0.0004 = (p_f + p_o)^2$$\nTo find the total frequency of pathogenic alleles, we take the square root of both sides. Since allele frequencies are non-negative, we only consider the positive root.\n$$\\sqrt{0.0004} = p_f + p_o$$\n$$0.02 = p_f + p_o$$\nWe are given $p_f = 0.01$. We can now solve for $p_o$, the aggregate frequency of the other pathogenic alleles.\n$$p_o = 0.02 - p_f = 0.02 - 0.01 = 0.01$$\nThe use of \"minimum\" in the prompt is consistent with this result; under the specified simple model (full penetrance, HWE), this is the only possible value. Any departure from this model, such as reduced penetrance, would require a higher allele frequency to produce the same prevalence, making our calculated value the minimum required.\nRounding to three significant figures, the frequency is $0.0100$.",
            "answer": "$$\\boxed{\\begin{pmatrix} 0.000100 & 0.0100 \\end{pmatrix}}$$"
        },
        {
            "introduction": "Identifying the specific genes responsible for inherited forms of glaucoma is a cornerstone of molecular ophthalmology, historically reliant on pedigree-based linkage analysis. This practice provides a deep dive into the statistical methodology used to map disease genes by calculating a two-point Logarithm of the Odds (LOD) score . Working through a three-generation pedigree, you will grapple with core genetic concepts like autosomal dominant inheritance, incomplete penetrance, and recombination fraction to quantify the evidence for linkage.",
            "id": "4692799",
            "problem": "A three-generation pedigree has been ascertained through a proband with normal-tension glaucoma (NTG). Molecular testing shows a heterozygous TANK-binding kinase 1 (TBK1) duplication in several family members. Assume an autosomal dominant disease model with age-dependent penetrance for carriers equal to $f_{1} = 0.6$ by the ascertainment age, and a negligible phenocopy rate for non-carriers by that age, $f_{0} = 0$. The TBK1 duplication is very rare in the general population, so no homozygotes are expected in this pedigree. All listed individuals are older than the age threshold at which $f_{1}$ applies. \n\nThe observed genotypes (presence or absence of the TBK1 duplication) and phenotypes (affected or unaffected with NTG) are:\n\n- Generation I:\n  - I-1: duplication carrier, affected.\n  - I-2: non-carrier, unaffected.\n- Generation II (children of I-1 and I-2):\n  - II-1: duplication carrier, affected.\n  - II-2: duplication carrier, unaffected.\n  - II-3: non-carrier, unaffected.\n- Generation II spouse and Generation III (children of II-1 with an unrelated unaffected non-carrier spouse II-4):\n  - II-4: non-carrier, unaffected.\n  - III-1: duplication carrier, affected.\n  - III-2: non-carrier, unaffected.\n\nAssume the coupling phase in I-1 is such that the NTG susceptibility allele (if present at a distinct disease locus) is on the same chromosomal homolog as the TBK1 duplication. Let $\\theta$ denote the recombination fraction between the duplication and the disease locus. Use Mendelian transmission and the penetrance model above, and condition on the observed founder phenotypes and genotypes (ascertainment through I-1), so that the likelihood is computed from the transmissions to the five non-founder offspring listed (II-1, II-2, II-3, III-1, III-2).\n\nCompute the two-point logarithm of the odds (LOD) score defined as \n$$Z(\\theta) = \\log_{10}\\!\\left(\\frac{L(\\text{data}\\mid \\theta)}{L(\\text{data}\\mid 0.5)}\\right),$$ \nat $\\theta = 0$, where $L(\\text{data}\\mid \\theta)$ is the pedigree likelihood of the observed offspring genotypes and phenotypes given $\\theta$ and the penetrance model, and $L(\\text{data}\\mid 0.5)$ is the corresponding likelihood under no linkage. Round your final answer to four significant figures.",
            "solution": "The user wants me to compute the logarithm of the odds (LOD) score for a given pedigree at a recombination fraction $\\theta = 0$.\n\n### Step 1: Extract Givens\n- **Disease Model**: Autosomal dominant inheritance.\n- **Marker**: A rare heterozygous TANK-binding kinase 1 (TBK1) duplication. We denote the duplication allele as $M$ and the normal allele as $m$.\n- **Disease Locus**: A hypothetical susceptibility allele, denoted $D$, and a normal allele, $d$.\n- **Penetrance**: The probability of being affected for a carrier of the disease allele $D$ is $f_{1} = P(\\text{Affected} | D/d) = 0.6$. Consequently, the probability of being unaffected is $1 - f_{1} = 0.4$.\n- **Phenocopy Rate**: The probability of being affected for a non-carrier of the disease allele $D$ is $f_{0} = P(\\text{Affected} | d/d) = 0$. Consequently, the probability of being unaffected is $1 - f_{0} = 1$.\n- **Founder I-1**: Carrier of the duplication ($M/m$) and affected. His genotype is assumed to be $D/d$. The problem specifies a coupling phase, meaning his haplotypic constitution is $(DM)/(dm)$.\n- **Founder I-2**: Non-carrier of the duplication ($m/m$) and unaffected. Her genotype is $d/d$, and her haplotype is $(dm)/(dm)$.\n- **Spouse II-4**: Unrelated, unaffected non-carrier. His genotype is assumed to be $d/d$ and $m/m$, with haplotype $(dm)/(dm)$.\n- **Offspring Data (the \"data\")**:\n  - II-1: Duplication carrier, affected.\n  - II-2: Duplication carrier, unaffected.\n  - II-3: Non-carrier, unaffected.\n  - III-1: Duplication carrier, affected (child of II-1 and II-4).\n  - III-2: Non-carrier, unaffected (child of II-1 and II-4).\n- **Recombination Fraction**: $\\theta$ is the recombination fraction between the marker locus ($M/m$) and the disease locus ($D/d$).\n- **LOD Score Definition**: $Z(\\theta) = \\log_{10}\\!\\left(\\frac{L(\\text{data}\\mid \\theta)}{L(\\text{data}\\mid 0.5)}\\right)$.\n- **Objective**: Compute $Z(\\theta)$ at $\\theta = 0$.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded**: The problem uses standard concepts from human genetics, including autosomal dominant inheritance, incomplete penetrance, recombination, and LOD score analysis. The association of TBK1 with glaucoma is a subject of scientific research. The setup is scientifically plausible.\n- **Well-Posed**: The problem provides all necessary information (pedigree structure, genotypes, phenotypes, penetrance model, founder phase) to calculate the likelihood and, subsequently, the LOD score. The question is specific and has a unique answer.\n- **Objective**: The problem is stated in precise, objective language.\n\nThe potential ambiguity regarding the TBK1 duplication being a marker for a \"distinct disease locus\" versus being the causal mutation itself is a standard feature of linkage analysis. The LOD score framework is designed to test for linkage by modeling a marker and a hypothetical disease locus separated by a recombination fraction $\\theta$. The case $\\theta=0$ represents perfect linkage, which is functionally equivalent to the marker being the disease gene itself. Thus, there is no contradiction. The problem is valid.\n\n### Step 3: Proceed to Solution\n\nTo compute $Z(0)$, we first need to derive the likelihood function $L(\\text{data}|\\theta)$, which is the probability of observing the phenotypes and genotypes of the five specified offspring, given the model parameters.\n\nThe total likelihood of the pedigree can be factored by sibships and independent branches. The offspring II-2 and II-3 are independent of the lineage descending from II-1. The likelihood is thus:\n$$L(\\text{data} | \\theta) = P(O_{II-2}) \\times P(O_{II-3}) \\times P(O_{II-1}, O_{III-1}, O_{III-2})$$\nwhere $O_i$ denotes the observation for individual $i$. The joint probability for the II-1 lineage must be computed by summing over the unobserved full genotypes of II-1, using the law of total probability, as formalized by the Elston-Stewart algorithm.\n\nThe mating I-1 ($(DM)/(dm)$) x I-2 ($(dm)/(dm)$) produces four types of gametes from I-1:\n- Non-recombinant gamete $(DM)$ with probability $\\frac{1-\\theta}{2}$.\n- Non-recombinant gamete $(dm)$ with probability $\\frac{1-\\theta}{2}$.\n- Recombinant gamete $(Dm)$ with probability $\\frac{\\theta}{2}$.\n- Recombinant gamete $(dM)$ with probability $\\frac{\\theta}{2}$.\nI-2 produces only $(dm)$ gametes.\n\nLet's calculate the probability (likelihood contribution) of observing each offspring type from such a mating.\n\n1.  **Carrier, Affected (e.g., II-1, III-1)**:\n    - Inherits $M$. This happens if the gamete from the informative parent is $(DM)$ (non-recombinant) or $(dM)$ (recombinant).\n    - Path 1: Inherits $(DM)$, genotype is $(DM)/(dm)$, i.e., $D/d$. Phenotype is \"Affected\" with probability $f_1=0.6$. The probability of this path is $\\frac{1-\\theta}{2} \\times 0.6$.\n    - Path 2: Inherits $(dM)$, genotype is $(dM)/(dm)$, i.e., $d/d$. Phenotype is \"Affected\" with probability $f_0=0$. The probability of this path is $\\frac{\\theta}{2} \\times 0 = 0$.\n    - Total probability: $L_{ca}(\\theta) = \\frac{0.6(1-\\theta)}{2} + 0 = 0.3(1-\\theta)$.\n\n2.  **Carrier, Unaffected (e.g., II-2)**:\n    - Path 1: Inherits $(DM)$, genotype $D/d$. Phenotype \"Unaffected\" with probability $1-f_1=0.4$. Probability of path: $\\frac{1-\\theta}{2} \\times 0.4$.\n    - Path 2: Inherits $(dM)$, genotype $d/d$. Phenotype \"Unaffected\" with probability $1-f_0=1$. Probability of path: $\\frac{\\theta}{2} \\times 1$.\n    - Total probability: $L_{cu}(\\theta) = \\frac{0.4(1-\\theta)}{2} + \\frac{\\theta}{2} = 0.2(1-\\theta) + 0.5\\theta = 0.2 + 0.3\\theta$.\n\n3.  **Non-carrier, Unaffected (e.g., II-3, III-2)**:\n    - A non-carrier does not have the $M$ allele. Gamete from the informative parent must be $(dm)$ (non-recombinant) or $(Dm)$ (recombinant).\n    - Path 1: Inherits $(dm)$, genotype $d/d$. Phenotype \"Unaffected\" with probability $1-f_0=1$. Probability of path: $\\frac{1-\\theta}{2} \\times 1$.\n    - Path 2: Inherits $(Dm)$, genotype $D/d$. Phenotype \"Unaffected\" with probability $1-f_1=0.4$. Probability of path: $\\frac{\\theta}{2} \\times 0.4$.\n    - Total probability: $L_{nu}(\\theta) = \\frac{1-\\theta}{2} + \\frac{0.4\\theta}{2} = 0.5(1-\\theta) + 0.2\\theta = 0.5 - 0.3\\theta$.\n\nThe likelihood of the entire pedigree is calculated by combining these probabilities. A crucial point is that II-1 is a parent in the third generation. His full genotype is not observed but can be inferred. Since II-1 is \"carrier, affected\", and the probability of being affected with a $(dM)/(dm)$ genotype is $0$, he must have the genotype $(DM)/(dm)$. This means he is a non-recombinant offspring of I-1.\nThis simplifies the likelihood calculation for his offspring (III-1, III-2), as the mating is II-1 ($(DM)/(dm)$) x II-4 ($(dm)/(dm)$), which is genetically identical to the I-1 x I-2 mating.\n\nThe likelihood of the data for all five offspring is the product of their individual probabilities of occurring:\n$$L(\\text{data}|\\theta) = L_{II-1}(\\theta) \\times L_{II-2}(\\theta) \\times L_{II-3}(\\theta) \\times L_{III-1}(\\theta) \\times L_{III-2}(\\theta)$$\nSubstituting the observations:\n- II-1: carrier, affected $\\implies L_{ca}(\\theta) = 0.3(1-\\theta)$\n- II-2: carrier, unaffected $\\implies L_{cu}(\\theta) = 0.2+0.3\\theta$\n- II-3: non-carrier, unaffected $\\implies L_{nu}(\\theta) = 0.5-0.3\\theta$\n- III-1: carrier, affected $\\implies L_{ca}(\\theta) = 0.3(1-\\theta)$\n- III-2: non-carrier, unaffected $\\implies L_{nu}(\\theta) = 0.5-0.3\\theta$\n\nThe full likelihood function is:\n$$L(\\text{data}|\\theta) = [0.3(1-\\theta)]^2 \\times [0.2+0.3\\theta] \\times [0.5-0.3\\theta]^2$$\n\nNow, we evaluate this function at $\\theta = 0$ and $\\theta = 0.5$.\n\n**Likelihood at $\\theta = 0$ (complete linkage):**\n$$L(\\text{data}|0) = [0.3(1-0)]^2 \\times [0.2+0.3(0)] \\times [0.5-0.3(0)]^2$$\n$$L(\\text{data}|0) = (0.3)^2 \\times (0.2) \\times (0.5)^2$$\n$$L(\\text{data}|0) = 0.09 \\times 0.2 \\times 0.25$$\n$$L(\\text{data}|0) = 0.018 \\times 0.25 = 0.0045$$\n\n**Likelihood at $\\theta = 0.5$ (no linkage):**\n$$L(\\text{data}|0.5) = [0.3(1-0.5)]^2 \\times [0.2+0.3(0.5)] \\times [0.5-0.3(0.5)]^2$$\n$$L(\\text{data}|0.5) = [0.3(0.5)]^2 \\times [0.2+0.15] \\times [0.5-0.15]^2$$\n$$L(\\text{data}|0.5) = (0.15)^2 \\times (0.35) \\times (0.35)^2$$\n$$L(\\text{data}|0.5) = (0.15)^2 \\times (0.35)^3$$\n$$L(\\text{data}|0.5) = 0.0225 \\times 0.042875 = 0.0009646875$$\n\n**Compute the LOD score $Z(0)$:**\nThe ratio of the likelihoods is:\n$$\\frac{L(\\text{data}|0)}{L(\\text{data}|0.5)} = \\frac{0.0045}{0.0009646875}$$\nTo avoid potential rounding errors, we can use fractions:\n$L(0) = (\\frac{3}{10})^2 \\times (\\frac{2}{10}) \\times (\\frac{5}{10})^2 = \\frac{9}{100} \\times \\frac{1}{5} \\times \\frac{1}{4} = \\frac{9}{2000}$.\n$L(0.5) = (\\frac{15}{100})^2 \\times (\\frac{35}{100})^3 = (\\frac{3}{20})^2 \\times (\\frac{7}{20})^3 = \\frac{9}{400} \\times \\frac{343}{8000} = \\frac{3087}{3200000}$.\nThe ratio is:\n$$\\frac{9/2000}{3087/3200000} = \\frac{9}{2000} \\times \\frac{3200000}{3087} = \\frac{9 \\times 1600}{3087}$$\nSince $3087 = 9 \\times 343$, the ratio simplifies to:\n$$\\frac{1600}{343}$$\nNow, we compute the LOD score:\n$$Z(0) = \\log_{10}\\left(\\frac{1600}{343}\\right)$$\n$$Z(0) \\approx \\log_{10}(4.664723)$$\n$$Z(0) \\approx 0.6688226$$\nRounding the result to four significant figures gives $0.6688$.",
            "answer": "$$\\boxed{0.6688}$$"
        }
    ]
}